Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) CEO Rensheng Jiang, the Company's Largest Shareholder Sees 7.3% Reduction in Holdings Value

Simply Wall StNov 20 19:28 ET

Zhifei Biotech: Report for the third quarter of 2024

SZSIOct 25 12:00 ET · Announcements

Chongqing Zhifei Biological Products (300122.SZ): Adjuvanted Quadrivalent Influenza Vaccine Approved for Clinical Trials.

chongqing zhifei biological products (300122.SZ) announced that it was developed by its wholly-owned subsidiary, anhui zhifei dragon horse biological pharmaceutical limited...

Zhitong FinanceOct 25 11:22 ET

Chongqing Zhifei Biological Products (300122.SZ): net income in the first three quarters was 2.151 billion yuan, a year-on-year decrease of 67.07%.

On October 25, Gelonhui reported on Chongqing Zhifei Biological Products (300122.SZ) third quarter report for 2024, with the company achieving revenue of 22.786 billion yuan in the first three quarters, a decrease of 41.98% year-on-year; net income attributable to shareholders of the listed company was 2.151 billion yuan, a decrease of 67.07% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.143 billion yuan, a decrease of 66.41% year-on-year; basic earnings per share were 0.8976 yuan.

Gelonghui FinanceOct 25 08:17 ET

Express News | Zhifei Biological Products Says Q3 Net Loss at 83.7 Mln Yuan

ReutersOct 25 07:34 ET

These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well

Simply Wall StOct 18 21:42 ET